{"schema_version":"secwatch.filing_event.v1","accession":"0001110803-22-000045","form_type":"8-K","ticker":"ILMN","cik":"0001110803","company_name":"ILLUMINA, INC.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.644039+00:00","generated_at":"2026-06-22T07:56:01.284733+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Illumina Q3 revenue $1.12B (+1% YoY); GAAP EPS -$24.26 on $3.91B GRAIL goodwill impairment","bullets":["GAAP diluted loss per share of $(24.26) vs. income of $2.08 in Q3 2021, driven by $3.91B goodwill impairment for GRAIL segment.","Non-GAAP diluted EPS of $0.34, down from $1.45; revenue $1.115B, up 1% reported and 3% constant currency.","Full-year FY2022 guidance: revenue flat to +1% YoY; GAAP EPS loss $(26.56)-$(26.41); non-GAAP EPS $2.35-$2.50.","50 NovaSeq X orders received; management expects macro headwinds to continue into 2023.","Consolidated GRAIL results included; GAAP gross margin 64.3% vs 69.5% YoY; operating margin -327.9%."],"urls":{"canonical":"https://secwatch.observer/filing/0001110803-22-000045","json":"https://secwatch.observer/filing/0001110803-22-000045.json","markdown":"https://secwatch.observer/filing/0001110803-22-000045.md","text":"https://secwatch.observer/filing/0001110803-22-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1110803/000111080322000045/0001110803-22-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1110803/000111080322000045/ilmn-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T07:56:01.284733+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e42b04c366bcfd1ce7b7665faa8d98cc78e6112","claim":"ILLUMINA, INC. reported third quarter ended October 2, 2022 results: revenue $1.12 billion, net income $ (3,816), EPS $(24.26). Guidance initiated.","evidence_excerpt":"Illumina Reports Financial Results for Third Quarter of Fiscal Year 2022 • Revenue of $1.12 billion for Q3 2022, up 1% from Q3 2021, and up 3% on a constant currency basis • GAAP diluted loss per share of $(24.26) for Q3 2022, compared to GAAP diluted earnings per share of $2.08 for Q3 2021; GAAP diluted loss per share for Q3 2022 includes goodwill impairment of $3.91 billion related to the GRAIL segment • Non-GAAP diluted earnings per share of $0.34 for Q3 2022, compared to non-GAAP diluted earnings per share of $1.45 for Q3 2021 • Expect full year revenue for fiscal year 2022 to be flat to 1% higher compared to fiscal year 2021, primarily reflecting year-to-date growth in sequencing consumables revenue, largely offset by a fourth quarter decline in select research project sample volume; delayed purchases ahead of the upcoming availability of NovaSeq X and from customer inventory and capital management; and incremental foreign exchange headwinds • Expect GAAP diluted loss per share of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1110803/000111080322000045/0001110803-22-000045-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended October 2, 2022"},{"label":"Revenue","value":"$1.12 billion"},{"label":"Net income","value":"$ (3,816)"},{"label":"EPS","value":"$(24.26)"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}